Dana-Farber Cancer Institute (DFCI), Brigham & Women's Hospital — Boston, Massachusetts

Dana-Farber Cancer Institute (DFCI), Brigham & Women's Hospital is a clinical research site located in Boston, Massachusetts, United States 02114.

Crixeo Health Trust Score: 58/100 (POOR). This profile has not yet been claimed by the site owner.

Dana-Farber Cancer Institute (DFCI), Brigham & Women's Hospital has participated in 1 clinical trials.

Therapeutic areas: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Burkitt Lymphoma.

Sponsors: Medical College of Wisconsin.

Sponsor Feasibility Report

Trust Score: 58/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana-Farber Cancer Institute (DFCI), Brigham & Women's Hospital?

Dana-Farber Cancer Institute (DFCI), Brigham & Women's Hospital has a Crixeo Trust Score of 58/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana-Farber Cancer Institute (DFCI), Brigham & Women's Hospital conducted?

Dana-Farber Cancer Institute (DFCI), Brigham & Women's Hospital has 1 clinical trials on record. Their work covers Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Burkitt Lymphoma.

Is Dana-Farber Cancer Institute (DFCI), Brigham & Women's Hospital accredited by Crixeo Health?

Dana-Farber Cancer Institute (DFCI), Brigham & Women's Hospital has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana-Farber Cancer Institute (DFCI), Brigham & Women's Hospital?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.